Phase 4 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are currently active patients at the Rocky Mountain MS Center (RMMSC) at the time of giving final study consent.
- People who are between 18 and 55 years old at the time of giving final study consent.
- People who have been diagnosed with primary progressive or relapsing multiple sclerosis (MS), as defined by a specific set of medical guidelines from 2017.
- People who have already received at least their first 600 mg dose of the medication ocrelizumab.
- People who are living in the Denver metro, Fort Collins, or Colorado Springs area at the time of giving final study consent.
- People whose MS-related disability falls within a certain range on a patient-reported scale called the Patient Determined Disease Steps (PDDS), scoring between 0 and 6.5.
- People who are able to complete written questionnaires that have been developed and validated in English.
- People who are able and willing to give informed consent using an electronic signature, in line with local and FDA requirements.
- People whose treating neurologist at RMMSC considers it medically appropriate to continue ocrelizumab treatment at the time of giving final study consent.
Who may not be able to join:
- People who are pregnant, planning to become pregnant, or breastfeeding at the time of giving final study consent or on the day of the infusion.
- People who have previously taken part in the SaROD trial at the RMMSC site.
- People whose blood test results, processed by a University of Colorado Hospital laboratory, are considered by their treating neurologist at RMMSC to make a home infusion medically inappropriate (confirm with trial site for details on which specific results apply).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Timothy L Vollmer, MD, University of Colorado, Denver
Phone: 303-724-2635
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Severe infusion reactions; Infusion reactions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.